Literature DB >> 9192164

Porcine model of proliferative vitreoretinopathy with platelets.

A García-Layana1, J C Pastor, M A Saornil, G Gonzalez.   

Abstract

PURPOSE: To develop an experimental model of proliferative vitreoretinopathy (PVR) in the pig, and determine the efficacy of platelet-derived growth factor (PDGF) compared with different platelet plasma concentrates in its development.
METHODS: Animals were divided into four groups of 12 pigs each. Group 1, 2, and 3 underwent four 3-mm-long retinotomies, a partial mechanical vitrectomy, and six transconjunctival retinal cryoapplications and were injected intravitreally with, respectively, 0.2 ml of platelet rich plasma, 0.2 ml of a solution containing 200 ng of porcine PDGF, and 0.2 ml of platelet concentrated plasma. Group 4 received only an intravitreal injection of 0.2 ml of porcine PDGF.
RESULTS: In Group 1, retinal detachments (RDs) developed in six eyes (50%) (two eyes, total RDs; four, extensive RDs). In Group 2, focal RDs developed in six eyes (50%). In Group 3, 11 eyes (92%) developed Rds (six eyes, total RDs; three, extensive RDs, two, focal RDs). Group 4, did not develop lesions. Statistically significant differences were found between Group 3 and the other groups. Group 2 RDs were associated with the presence of vitreoretinal membranes but there were no signs of PVR. In Groups 1 and 3, signs of anterior PVR, posterior PVR, and retinal holes with rolled edges were observed.
CONCLUSIONS: We have developed a model of PVR in the pig, the retina of which more closely resembles that of humans. Platelet plasma more effectively contributed to the development of an experimental model of porcine PVR than 200 ng of PDGF. The efficacy depends on the platelet concentration of the plasma. These results suggest that other growth factors and plasma components may interact synergistically with PDGF in the pathogenesis of PVR.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9192164     DOI: 10.1076/ceyr.16.6.556.5082

Source DB:  PubMed          Journal:  Curr Eye Res        ISSN: 0271-3683            Impact factor:   2.424


  7 in total

1.  Ultrastructure of the vitreoretinal interface following plasmin assisted vitrectomy.

Authors:  A Gandorfer; E Putz; U Welge-Lüssen; M Grüterich; M Ulbig; A Kampik
Journal:  Br J Ophthalmol       Date:  2001-01       Impact factor: 4.638

2.  A battery of cell- and structure-specific markers for the adult porcine retina.

Authors:  Ulrica Englund Johansson; Sajedeh Eftekhari; Karin Warfvinge
Journal:  J Histochem Cytochem       Date:  2010-01-19       Impact factor: 2.479

3.  Müller and macrophage-like cell interactions in an organotypic culture of porcine neuroretina.

Authors:  Ivan Fernandez-Bueno; Jose Carlos Pastor; Manuel Jose Gayoso; Ignacio Alcalde; Maria Teresa Garcia
Journal:  Mol Vis       Date:  2008-11-28       Impact factor: 2.367

4.  Human cytokines activate JAK-STAT signaling pathway in porcine ocular tissue.

Authors:  Elizaveta Fasler-Kan; Natasha S Barteneva; Sylvia Ketterer; Kerstin Wunderlich; Anca Reschner; Asil Nurzhanova; Josef Flammer; Jörg Huwyler; Peter Meyer
Journal:  Xenotransplantation       Date:  2013-11-01       Impact factor: 3.907

5.  Assessment of Ocriplasmin Effects on the Vitreoretinal Compartment in Porcine and Human Model Systems.

Authors:  Bart Jonckx; Michael Porcu; Aurelie Candi; Isabelle Etienne; Philippe Barbeaux; Jean H M Feyen
Journal:  J Ophthalmol       Date:  2017-10-29       Impact factor: 1.909

Review 6.  Inflammatory and Fibrogenic Factors in Proliferative Vitreoretinopathy Development.

Authors:  Rishika Chaudhary; Robert A H Scott; Graham Wallace; Martin Berry; Ann Logan; Richard J Blanch
Journal:  Transl Vis Sci Technol       Date:  2020-02-21       Impact factor: 3.283

7.  Endogenous or Exogenous Retinal Pigment Epithelial Cells: A Comparison of Two Experimental Animal Models of Proliferative Vitreoretinopathy.

Authors:  Chee Wai Wong; Joanna Marie Fianza Busoy; Ning Cheung; Veluchamy Amutha Barathi; Gert Storm; Tina T Wong
Journal:  Transl Vis Sci Technol       Date:  2020-08-31       Impact factor: 3.283

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.